TU 31 - new oncology molecule
New Platinum Complex TU31 for the Treatment of Solid Tumors via Oral Administration
Phase I clinical evaluation is underway for the new platinum complex TU31 via oral administration, EU number 2024-511215-21-00, acronym PERPETUM. The clinical evaluation (CE) is conducted by the Masaryk Memorial Cancer Institute in Brno. The Faculty of Medicine at Masaryk University in Brno and REKNOS Science s.r.o. Brno are collaborating on the CE, and the sponsor of the CE is VUAB Pharma a.s.
Brno
Development and production of cytostatic APIs and intermediates
Dacarbazine
Development of new platinum-based drugs
Czech quality for better health worldwide
The excellent reputation that VUAB Pharma a.s. has earned in the field of the pharmaceutical industry is based on its tradition, experience, and responsible approach to employees.
About us